Compare ARK Space & Defense Innovation ETF (ARKX) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Space & Defense Innovation ETF vs IDEXX Laboratories, Inc. — how do they compare? ARK Space & Defense Innovation ETF trades at $34.7, while IDEXX Laboratories, Inc. trades at $588.36 (market cap $46.22B). The key difference: ARK Space & Defense Innovation ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| ARKX | IDXX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $37.74 | $766.68 |
52-Week Low | $25.46 | $526.44 |
Market Cap | — | $46.22B |
Enterprise Value | — | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARK Space & Defense Innovation ETF (ARKX) trades at $34.8, up 1.13% today, with a bullish technical signal driven by strong moving average alignment. The ETF focuses on space economy exposure, including holdings like SpaceX (8.31%) and Rocket Lab (6.27%), benefiting from growing commercial and defense space investments. Recent news highlights competition with other space ETFs and the impact of SpaceX's IPO on the sector.
Outlook remains positive due to thematic tailwinds in space innovation, but high volatility and stretched valuations in key holdings pose risks. Investors gain diversified access to a high-growth theme, though expense ratios and sector concentration require careful consideration amid market fluctuations.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Space & Defense Innovation ETF
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
